References
- Puranik A, Lenehan PJ, Silvert E, et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of alpha and delta variant prevalence.medRxiv. 2021. DOI:10.1101/2021.08.06.21261707
- Schechtman E. Odds ratio, relative risk, absolute risk reduction, and the number needed to treat-which of these should we use? Value Health. 2002;5(5):431–436.
- Ranganathan P, Pramesh CS, Aggarwal R. Common pitfalls in statistical analysis: absolute risk reduction, relative risk reduction, and number needed to treat. Perspect Clin Res. 2016;7(1):51–53.
- Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother. 2010;1(2):100–107.
- von Elm E, Altman DG, Egger M, STROBE Initiative, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLOS Med. 2007;4(10):e296.
- Shamseer L, Hopewell S, Altman DG, et al. Update on the endorsement of CONSORT by high impact factor journals: a survey of journal “‘Instructions to Authors’ in 2014”. Trials. 2016;17(1):301.
- Schwartz LM, Woloshin S, Dvorin EL, et al. Ratio measures in leading medical journals: structured review of accessibility of underlying absolute risks. BMJ. 2006;333(7581):1248.
- Jaeschke R, Guyatt G, Shannon H, et al. Basic statistics for clinicians: 3. Assessing the effects of treatment: measures of association. CMAJ. 1995;152(3):351–357.
- King NB, Harper S, Young ME. Use of relative and absolute effect measures in reporting health inequalities: structured review. BMJ. 2012;345:e5774.
- Alonso-Coello P, Carrasco-Labra A, Brignardello-Petersen R, et al. Systematic reviews experience major limitations in reporting absolute effects. J Clin Epidemiol. 2016;72:16–26.
- Vinkers CH, Lamberink HJ, Tijdink JK, et al. The methodological quality of 176,620 randomized controlled trials published between 1966 and 2018 reveals a positive trend but also an urgent need for improvement. PLoS Biol. 2021;19(4):e3001162.
- Saleem MD, Kesty C, Feldman SR. Relative versus absolute risk of comorbidities in patients with psoriasis. J Am Acad Dermatol. 2017;76(3):531–537.
- Tjahjono LA, Cline A, Huang WW, et al. Rosacea: relative risk versus absolute risk of malignant comorbidities. J Am Acad Dermatol. 2019;81(2):623–624.
- Egeberg A, Hansen PR, Gislason GH, et al. Patients with rosacea have increased risk of dementia. Ann Neurol. 2016;79(6):921–928.